Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab

Summary

Pathos AI signed back-to-back cancer contracts with AstraZeneca and Jiangsu Alphamab Biopharmaceuticals, potentially worth over $2 billion for a late-stage bispecific antibody-drug conjugate for breast cancer, though AstraZeneca deal terms were undisclosed.